Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects ...

A new class of weight-loss drug just took a major step toward approval for use. In a phase 3 clinical trial, the medication retatrutide helped control blood sugar levels in participants with type 2 ...

Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...

This is read by an automated voice. Please report any issues or inconsistencies here. The Phase 3 trial establishes an objective milestone for non-surgical weight loss interventions. Multi-receptor ...

Youve heard of the popular glucagon-like peptide-1 (GLP-1) receptor agonist drug semaglutide (Ozempic, Wegovy) and GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound). Now theres a new kid on the weight ...

Jessica Rendall is a reporter with experience covering a variety of health and wellness topics, including chronic disease, infectious disease, telemedicine, mental health and health technology. Carley ...

Please provide your email address to receive an email when new articles are posted on . Retatrutide was tied to weight loss ranging from 19% with a 4 mg dose to 28.3% with a 12 mg dose at 80 weeks. Of ...

Some people taking the investigational medication retatrutide lost an average of 30 percent of their body weight in about 2 years. The medication offers weight reduction on par with bariatric surgery.

Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug ...

Please provide your email address to receive an email when new articles are posted on . Adults with obesity and knee osteoarthritis had reductions in body weight and knee pain with retatrutide. More ...